Pregnancy and Contraception Education in Chronic Kidney Disease (PACE-CKD)
Launched by UNIVERSITY OF MICHIGAN · Dec 18, 2023
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
The PACE-CKD trial is a study designed to help women with chronic kidney disease (CKD) understand their options regarding pregnancy and contraception. The goal is to see if a special educational tool can assist patients in making informed decisions about their reproductive health. This pilot study is currently looking for female participants between the ages of 18 and 45 who have been diagnosed with CKD, which means their kidneys are not functioning properly for more than three months. However, individuals who are currently on dialysis, have had a kidney transplant, are pregnant, or cannot participate due to cognitive or visual impairments are not eligible for this study.
If you decide to participate, you will have the chance to use this educational tool that is designed to be easy to understand and supportive of your health decisions. Your feedback will help researchers learn how effective and acceptable this tool is for future studies. This could lead to better resources for women with CKD in the future. If you’re interested and meet the eligibility criteria, this could be a valuable opportunity to contribute to important research while learning more about your options.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Any Chronic Kidney Disease (CKD) diagnosis
- * CKD defined as abnormality in kidney structure or function for \>3 months and may be manifested by having any one of the following:
- • i. Glomerular filtration rate (GFR)\<60 milliliter/Minute (ml/min)/1.73m2, or
- • ii. A marker of kidney damage (albuminuria \>30 milligrams per gram (mg/g), abnormal kidney histology by biopsy, hematuria, structural abnormalities by imaging (e.g. polycystic kidney disease, horseshoe kidney) or electrolyte abnormalities due to tubular disorders)
- • - Able to speak and read English
- Exclusion Criteria:
- • Patients receiving dialysis
- • Patients who have a kidney transplant
- • Patients that are surgically sterile (tubal ligation or hysterectomy) or currently pregnant
- • Patients that have significant cognitive or visual impairment that limits interaction with the decision aid (DA)
About University Of Michigan
The University of Michigan, a leading academic institution renowned for its commitment to advancing healthcare and medical research, serves as a prominent clinical trial sponsor. With a robust infrastructure that supports innovative research initiatives, the university leverages its multidisciplinary expertise to conduct a wide array of clinical trials aimed at improving patient outcomes and advancing medical knowledge. Through its state-of-the-art facilities and collaborative environment, the University of Michigan fosters partnerships between researchers, clinicians, and industry leaders, ensuring the development of cutting-edge therapies and interventions that address pressing health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ann Arbor, Michigan, United States
Patients applied
Trial Officials
Andrea Oliverio, MD, MSc
Principal Investigator
University of Michigan
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported